Avoro Capital
Overview
Avoro Capital is a global life sciences investment firm with a focus on supporting emerging biotechnology companies . The firm invests in companies ranging from pre-clinical to mature commercial stage, novel therapies . Avoro Capital Advisors LLC (“AVCAP”) is a Delaware limited liability company . AVCAP is managed and fully controlled by Dr. Behzad Aghazadeh .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Hemab Therapeutics | Feb 2023 | Series B | Co-investor |
| Scribe Therapeutics | Mar 2021 | Series B | Lead |
| Ottimo Pharma | Dec 2024 | Series A | Lead |
| Ethyreal Bio | Jun 2026 | Series B | Lead |
| Hemab Therapeutics | Oct 2025 | Series C | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Avoro Capital based?
Avoro Capital is headquartered in New York City, New York, United States.
When was Avoro Capital founded?
Avoro Capital was founded in 2009.
How many portfolio companies does Avoro Capital have?
Avoro Capital has 7 portfolio companies in Caplight's dataset.
What are some companies in Avoro Capital's portfolio?
Portfolio companies visible on Caplight include Hemab Therapeutics, Scribe Therapeutics, Ottimo Pharma, Ethyreal Bio, Hemab Therapeutics.
What was Avoro Capital's most recent investment shown here?
Avoro Capital's most recent investment in this portfolio sample was in Ethyreal Bio in 2026.
What sectors does Avoro Capital focus on?
Avoro Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Avoro Capital focus on?
Avoro Capital typically invests at the Mid stage.
What is Avoro Capital's AUM?
Avoro Capital's assets under management are estimated between $1.0B and $10.0B.